Pharmaceutical services firm Hvivo, formerly Open Orphan, will pay a dividend to shareholders after a “record financial and operational performance” last year.
The Dublin and London-listed organisation is set to pay a one-off special dividend of £3m (€3.4m) in June following “strong cash generation” in 2022.
Revenues rose by 30pc across the year to £50.7m, while the group’s cash position stood at £28.4m at the end of 2022, up from £15.7m in 2021.
hVIVO plc (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials, providing end-to-end early clinical development services for its broad and long-standing client base of biopharma companies.